All sponsors

Genfleet Therapeutics (Shanghai) Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS12
PHASE 3 / 2-33
RECRUITING8
READOUTS ≤12 MONTHS6
Open Genfleet Therapeutics (Shanghai) Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
GFH009
NCT06375733
P1/2RecruitingLarge B-cell Lymphoma512026-12-31
ArmA:GFH375
NCT07554859
P2Not yet recruitingNSCLC (Advanced Non-small Cell Lung Cancer)902027-04-30
GFH375
NCT07262567
P3RecruitingMetastatic Pancreatic Cancer3202027-06
GFH375
NCT07259590
P1/2RecruitingAdvanced Solid Tumors Cancer; PDAC1262027-07
GFH276
NCT07198321
P1/2RecruitingCancer; PDAC4502027-07-30 (-2 mo)
GFH276
NCT07678593
P1/2RecruitingAdvanced Solid Tumors Cancer; Pancreatic Ductal Adenocarcinoma2222027-11
GFH276X1203
NCT07846358
P1/2Not yet recruitingRAS Mutation; Non-small Cell Lung Cancer (NSCLC)842027-12
A Phase Ib/II
NCT07915921
P1/2Not yet recruitingCRC1502028-04-30
GFH375
NCT06500676
P1/2RecruitingKRAS G12D Mutations; Advanced Solid Tumors4072028-07-31
GFH375
NCT07784374
P2RecruitingPancreatic Cancer1202028-08-31
GFH375 + Cetuximab
NCT07913360
P3Not yet recruitingColorectal Cancer3682028-11
GFH375
NCT07668752
P3RecruitingKRAS G12D Mutation; NSCLC (Non-small Cell Lung Cancer)3002030-06-30